

Peter A Kaufman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8941781/publications.pdf>

Version: 2024-02-01

47
papers

2,934
citations

361413

20
h-index

289244

40
g-index

48
all docs

48
docs citations

48
times ranked

3951
citing authors

#	ARTICLE	IF	CITATIONS
1	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2 ⁺ Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2875-2884.	1.6	1,105
2	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 519-530.	10.7	441
3	Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. <i>Journal of Clinical Oncology</i> , 2015, 33, 594-601.	1.6	365
4	Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. <i>Cancer Research</i> , 2016, 76, 5933-5944.	0.9	105
5	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology</i> , The, 2018, 19, 812-824.	10.7	98
6	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1000-1000.	1.6	71
7	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. <i>Clinical Cancer Research</i> , 2021, 27, 3061-3068.	7.0	66
8	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. <i>Clinical Cancer Research</i> , 2019, 25, 2433-2441.	7.0	62
9	Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 875-883.	2.5	51
10	Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2 ⁻ negative breast cancer. <i>Cancer</i> , 2014, 120, 2657-2664.	4.1	47
11	Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 509-520.	2.5	46
12	Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor ⁺ -Positive, HER2 ⁻ Negative Advanced Breast Cancer After Endocrine Therapy. <i>Oncologist</i> , 2020, 25, e243-e251.	3.7	45
13	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. <i>Oncologist</i> , 2020, 25, e214-e222.	3.7	39
14	Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 461-470.	2.5	38
15	Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S39615.	1.1	36
16	â€œNewâ€•metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 150.	5.0	33
17	Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. <i>Journal of Biomedical Optics</i> , 2018, 24, 1.	2.6	32
18	Quantitative measurement of HER2 expression in breast cancers: comparison with â€œreal-worldâ€™ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. <i>Breast Cancer Research</i> , 2015, 17, 41.	5.0	29

#	ARTICLE	IF	CITATIONS
19	A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).. Journal of Clinical Oncology, 2020, 38, 1015-1015.	1.6	28
20	The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2â€“positive metastatic breast cancer. BMC Cancer, 2014, 14, 307.	2.6	21
21	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Research, 2015, 17, 133.	5.0	21
22	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clinical Cancer Research, 2020, 26, 1105-1113.	7.0	19
23	Effect of neuromuscular electrical stimulation on skeletal muscle size and function in patients with breast cancer receiving chemotherapy. Journal of Applied Physiology, 2020, 128, 1654-1665.	2.5	15
24	Goal Attainment and Goal Adjustment of Older Adults During Person-Directed Cancer Rehabilitation. American Journal of Occupational Therapy, 2018, 72, 7202205110p1-7202205110p8.	0.3	14
25	Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.. Journal of Clinical Oncology, 2018, 36, 1002-1002.	1.6	13
26	Collagen quantification in breast tissue using a 12-wavelength near infrared spectral tomography (NIRST) system. Biomedical Optics Express, 2017, 8, 4217.	2.9	10
27	Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Research and Treatment, 2020, 184, 559-565.	2.5	10
28	MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. Journal of Clinical Oncology, 2017, 35, 1000-1000.	1.6	10
29	Comparison of iron oxide nanoparticle and microwave hyperthermia alone or combined with cisplatin in murine breast tumors. , 2011, 7901, .		8
30	Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. Clinical Breast Cancer, 2018, 18, 433-440.e1.	2.4	8
31	Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.. Journal of Clinical Oncology, 2018, 36, 1049-1049.	1.6	8
32	Health Through Activity: Initial Evaluation of an In-Home Intervention for Older Adults With Cancer. American Journal of Occupational Therapy, 2019, 73, 7305205070p1-7305205070p11.	0.3	8
33	Microwave imaging for neoadjuvant chemotherapy monitoring. , 2006, , .		6
34	Incongruence between women's surveyâ€“and interviewâ€“determined decision control preferences: A mixed methods study of decisionâ€“making in metastatic breast cancer. Psycho-Oncology, 2018, 27, 1950-1957.	2.3	6
35	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Research and Treatment, 2021, 188, 179-190.	2.5	5
36	Differences between womenâ€™s preferred and actual experience with â€“shared decision-makingâ€™: A mixed method study.. Journal of Clinical Oncology, 2016, 34, 34-34.	1.6	5

#	ARTICLE	IF	CITATIONS
37	Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 2555-2555.	1.6	2
38	Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.. Journal of Clinical Oncology, 2018, 36, 1048-1048.	1.6	2
39	Correlation of near-infrared spectral tomography (NIRST) with residual cancer burden (RCB) for prognostic assessment subsequent to neoadjuvant chemotherapy (NAC) in breast cancer.. Journal of Clinical Oncology, 2018, 36, e12655-e12655.	1.6	2
40	Bispecific monoclonal antibody therapy (anti HER-2/neu Å– anti CD 64) for human breast cancers that overexpress HER-2/neu. Journal of Cellular Biochemistry, 1993, 53, 255-256.	2.6	1
41	Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma. , 1996, 78, 1906-1911.		1
42	Plasma DNA as a âœœliquid biopsyâ€•incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer. Breast Cancer Research and Treatment, 2020, 182, 665-677.	2.5	1
43	Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer. Cancer Research, 2022, 82, P2-14-18-P2-14-18.	0.9	1
44	Pre-treatment Near-Infrared Spectral Tomography (NIRST) to predict pathologic complete response to neoadjuvant chemotherapy (NAC) in women with locally advanced breast cancer (LABC).. Journal of Clinical Oncology, 2015, 33, 1047-1047.	1.6	0
45	Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).. Journal of Clinical Oncology, 2016, 34, 2548-2548.	1.6	0
46	Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry.. Journal of Clinical Oncology, 2017, 35, 239-239.	1.6	0
47	Evaluation of fixed-dose regimens of seribantumab in patients with solid tumors.. Journal of Clinical Oncology, 2018, 36, 2524-2524.	1.6	0